参麦注射液辅助治疗急性心肌梗死的临床研究

发布时间：2018-08-08 15:13

【摘要】：目的观察参麦注射液辅助治疗急性心肌梗死的临床疗效及安全性。方法将72例急性心肌梗死患者随机分为对照组35例和试验组37例。对照组予以吸氧、抗凝、抗血小板等治疗;试验组在对照组治疗的基础上,予以静脉滴注参麦注射液20 mL qd。2组患者均治疗2周。比较2组患者的临床疗效和药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为89.19%(33/37例)和71.43%(25/35例),差异有统计学意义(P0.05)。治疗后,试验组和对照组的左心室射血分数(LVEF)分别为(72.16±16.44)%,(58.43±20.06)%;E峰值分别为(88.40±8.89),(68.19±6.87)cm·s~(-1);E/A值分别为(1.27±0.13),(0.98±0.10),差异均有统计学意义(P0.05)。治疗后,试验组和对照组的A峰值分别为(69.61±7.03),(69.58±7.01)cm·s~(-1),差异无统计学意义(P0.05)。治疗期间,试验组发生的药物不良反应有口干、过敏、恶心,对照组发生的药物不良反应有口干、过敏、头痛。试验组和对照组的药物不良反应率分别为13.51%和8.57%,差异无统计学意义(P0.05)。结论参麦注射液辅助治疗急性心肌梗死有很好的临床疗效,且不增加药物不良反应的发生率。
[Abstract]:Objective to observe the clinical efficacy and safety of Shenmai injection in the treatment of acute myocardial infarction. Methods 72 patients with acute myocardial infarction were randomly divided into control group (n = 35) and trial group (n = 37). The control group was treated with oxygen inhalation, anticoagulant and anti-platelet therapy, and the experimental group was treated with 20 mL Shenmai injection by intravenous drip for 2 weeks on the basis of the control group. The clinical efficacy and adverse drug reactions were compared between the two groups. Results after treatment, the total effective rates of the experimental group and the control group were 89.19% (33 / 37 cases) and 71.43% (25 / 35 cases), respectively. The difference was statistically significant (P0.05). After treatment, the left ventricular ejection fraction (LVEF) was (72.16 卤16.44) and (58.43 卤20.06) the peak value of E was (88.40 卤8.89), (, 68.19 卤6.87) cm s-1 / A (1.27 卤0.13), (0.98 卤0.10) in the experimental group and the control group, respectively (P0.05). After treatment, the A peak value of experimental group and control group was (69.61 卤7.03), (卤69.58 卤7.01) cm s ~ (-1), the difference was not statistically significant (P0.05). During treatment, the adverse drug reactions occurred in the trial group were dry mouth, allergic, nausea, and the adverse drug reactions in the control group were dry mouth, allergy and headache. The adverse drug reaction rates of the test group and the control group were 13.51% and 8.57%, respectively. The difference was not statistically significant (P0.05). Conclusion Shenmai injection is effective in the treatment of acute myocardial infarction and does not increase the incidence of adverse drug reactions.
【作者单位】：黔南布依族苗族自治州人民医院心内科;贵州航空集团300医院心内科;
【基金】：黔南民族医学高等专科学校科研基金资助项目(QNYZ2014-21)
【分类号】：R542.22

【相似文献】